Skip to main content

Table 1 Features of the studies included

From: Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis

Author

Country

Year

Sample size (high/low PNI)

Cut-off value of PNI

Median (range) of PNI

Adjusted factors

Follow-up time (month)

Age (year)(range)

NOS score

Treatment

Stage

Survival outcome

Xiaoxiao Hao

China

2017

125/127

45

IPI, GPS, NLR, PNI, PI

49 (16–82)

6

R-CHOP;

CHOP/CHOP-like

I–IV

OS, PFS

Wenjuan Yu

China

2019

114/195

45

48.4 (23.9–86.2)

BMI, hemoglobin,

NCCI-IPI

7

R-CHOP

I–IV

OS

Se-Il Go

Korea

2019

69/159

40

Sarcopenia, albumin, ALC, BMI, IPI, B-symptoms

64 (21–88)

7

R-CHOP

I–IV

OS, PFS

Vlatka Periˇsa

Croatia

2017

75/28

44.55

50.26 (22.91–65.3)

Age, gender, IPI

ECOG-PS, LDH,

Ann Arbor stage,

B-symptoms

Median: 27 (range: 1–105)

63 (22–87)

6

R-CHOP/

R-CHOP-like

I–IV

OS, PFS

Qinjun Zhou

China

2016

129/124

44.675

-

B-symptoms, LDH,

Ann Arbor stage,

ECOG-PS,

extra-nodal, IPI

49 (19–81)

6

R‑CHOP

I–IV

OS, PFS

Teng Song

China

2019

44/38

44.15

ECOG-PS, Ann Arbor stage, LDH,IPI, ALC

59(23–79)

6

CHOP;

R-CHOP

I–IV

OS

Erina

Hamada

Japan

2020

38/46

41.3

Albumin, ALC, IPI, extra-nodal

ECOG-PS, LDH, gender, Ann Arbor stage, B-symptoms

Median: 39

84 (80–94)

6

R-CHOP;

R-CVP; R alone; palliative

I–IV

OS

  1. IPI International Prognostic Index, PNI Platelet Lymphocyte Ratio, PNI Prognostic Nutritional Index, GPS Glasgow prognostic score, PI Prognostic Index, NLR Neutrophil Lymphocyte Ratio, R-CHOP rituximab plus cyclophosphamide doxorubicin vincristine and prednisone, BMI Body Mass Index, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, PFS progression-free survival, OS overall survival, ALC Absolute lymphocyte count, NCCN National Comprehensive Cancer Network